Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioCryst nets $29.9mm in private placement

Executive Summary

BioCryst Pharmaceuticals (enzyme blockers for cancer and cardiovascular, autoimmune, and infectious diseases) netted $29.9mm through the private placement of 2.2mm common shares priced at $13.46 each (a 9% discount to market). Institutional investors included Kleiner Perkins Caufield & Byers and Texas Pacific Group Ventures.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies